AstraZeneca (AZN -0.31%) may pay a heft dividend, but the company has been facing a number of headwinds and regulatory setbacks lately. In the following video from the Motley Fool's health-care show, Market Checkup, analysts David Williamson and Max Macaluso discuss the partnerships that this company has been forming to boost its pipeline and the key to accelerating its turnaround.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
AstraZeneca: Lost Stock or Cheap Turnaround?
By Max Macaluso and Dave Williamson
–
Sep 19, 2013 at 7:04PM
NASDAQ: AZN
AstraZeneca Plc
Market Cap
$217B
Today's Change
(-0.31%) -$0.22
Current Price
$69.85
Price as of June 27, 2025, 4:00 p.m. ET
Can this big pharma company return to growth?
David Williamson and Max Macaluso, Ph.D. have no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
AstraZeneca Plc
AZN
$69.85
(-0.31%)
$0.22
Johnson & Johnson
JNJ
$152.45
(0.29%)
$0.44
Bristol Myers Squibb
BMY
$46.34
(-0.67%)
$0.31
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
3 No-Brainer Stocks to Buy for Under $100 Right Now
Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today
Forget the Correction: This Stock Is Defying the Sell-Off, and There Might Be More Upside Ahead
3 Magnificent Growth Stocks to Buy Right Now
What's a Good Price for AstraZeneca Stock?
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.